Shingrix

shingrix
Biotech

Curevo’s shingles vaccine equals Shingrix in ph. 2 head-to-head

When the small biotech Curevo decided to go up against GSK in the Shingles space it seemed like a bold move—but so far it’s paying off.
James Waldron Jan 8, 2024 9:44am
Publicly traded hotel companies beholden to Wall Street

Takeda spinout HilleVax hits Wall St., a test of choppy waters

Apr 7, 2022 10:48am
Vaccine

Curevo will go head-to-head against GSK's Shingrix with $60M

Feb 10, 2022 11:25am
Pfizer building

Pfizer, BioNTech team up against GSK's Shingrix dominance

Jan 5, 2022 9:49am
Flagship Pioneering office

Ex-GSK Shingrix chief Pfefer is Flagship's newest CEO-Partner

Jul 16, 2020 5:55pm